Skip to main content
. 2019 Jul 29;10(5):1893–1907. doi: 10.1007/s13300-019-0671-x

Table 1.

Statements that achieved consensus in the Delphi study

graphic file with name 13300_2019_671_Tab1a_HTML.jpg

graphic file with name 13300_2019_671_Tab1b_HTML.jpg

graphic file with name 13300_2019_671_Tab1c_HTML.jpg

S statement, SU sulfonylurea, HT hypertension, SGLT2-I sodium/glucose cotransporter-2 inhibitor, SBP systolic blood pressure, CV cardiovascular, HF heart failure, GLP1-RA glucagon-like peptide-1 receptor agonist, DPP4-I dipeptidyl peptidase-4 inhibitor, T2D type 2 diabetes, HbA1c glycated hemoglobin, BMI body mass index, eGFR estimated glomerular filtration rate, CKD chronic kidney disease, C consensus, NC non-consensus, A agreement, D disagreement

Clear grey font: First round results for those statements that achieved consensus on the second round

Black font: Consensus, either on first or second round

Italics: Statements reworded for the second round

*According to the order in which the statements were presented in the Delphi questionnaire

**Consensus close to the limit (66.6%)